The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (BIOADAPTOR RCT)

Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

Study Overview

• Status: Active, not recruiting
• Conditions: Coronary Artery Disease; Coronary Disease; Coronary Stenosis; Coronary Artery Stenosis
• Intervention / Treatment: Device: Percutaneous Coronary Intervention

Detailed Description

The Bioadaptor RCT Study is a prospective, 1:1 randomized study of parallel designed, that will enroll up to 444 patients requiring treatment of up to two de novo coronary lesions of ≤ 34 mm in length in vessels of ≥ 2.25 mm and ≤ 4.0 mm in diameter.

One or two designated target lesions, located in separate epicardial vessels (RCA, LCX or LAD), and meeting the inclusion/exclusion criteria may be treated with the ELX1805J (DynamX Bioadaptor) or Resolute Onyx stent

The primary safety endpoint is Target Lesion Failure (TLF) at 12 months. TLF is a composite endpoint defined as cardiac death, target vessel MI, and clinically-indicated target lesion revascularization

Additional secondary safety and effectiveness endpoints will be evaluated at 30 days, 6 and 12 months and 2-5 years.

Using visual assessment, the target lesion must measure ≥ 2.25 mm and ≤ 4.0 mm in diameter and ≤ 34 mm in length able to be covered by a single ELX1805J or Resolute Onyx stent including 2 mm of healthy vessel on either side of the planned treatment area.

The patient will be eligible for device implantation only after satisfactory lesion pre-dilatation defined as: ≥ TIMI 2 flow, and no dissection greater than Grade B (NHLBI) able to be covered with a single device

• Study Type: Interventional
• Enrollment (Estimated): 444
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Antwerp, Belgium
    • AZ Middelheim Hospital
  • Brugge, Belgium
    • AZ Sint Jan Brugge
  • Genk, Belgium
    • Ziekenhuis Oost-Limburg
  • Leuven, Belgium
    • Universitaire Ziekenhuizen Leuven
• Germany
  • Bad Nauheim, Germany
    • Kerkhoff Klinik GmbH
  • Bad Segeberg, Germany
    • Segeberger Kliniken Gmbh
  • Coburg, Germany
    • REGIOMED Klinikum Coburg
  • Dortmund, Germany
    • St. Johannes Hospital
  • Erlangen, Germany
    • Universitatsklinikum Erlangen
  • Essen, Germany
    • Elisabeth Krankenhaus Essen
  • Frankfurt, Germany
    • MVZ CCB Frankfurt
  • Giessen, Germany
    • Universitatsklinikun Giessen
  • Jena, Germany
    • Universitatsklinikum Jena
  • Kiel, Germany
    • UKSH Kiel Klinik
  • Mainz, Germany
    • Universitätsmedizin-Mainz
  • Trier, Germany
    • Krankenhaus der Barmherzigen Brüder
• Japan
  • Tokyo, Japan
    • Teikyo University Hospital
  • Tokyo, Japan
    • Cardiovascular Reaearch Institute
  • Fukuoka-Ken
    • Kitakyushu City, Fukuoka-Ken, Japan
      • Kokura Memorial Hospital
    • Kurume City, Fukuoka-Ken, Japan
      • Shinkoga Hospital
  • Hokkaido
    • Sapporo, Hokkaido, Japan
      • Sapporo Higashi Tokushukai Hospital
  • Ibaraki-Ken
    • Tsuchiura City, Ibaraki-Ken, Japan
      • Takahashi Hospital
    • Tsuchiura City, Ibaraki-Ken, Japan
      • Tsuchiura Kyodo Hospital
  • Kagoshima-Ken
    • Kagoshima City, Kagoshima-Ken, Japan
      • Tenyokai Central Hospital
  • Kanagawa-Ken
    • Kamakura City,, Kanagawa-Ken, Japan
      • Shonan Kamakura General Hospital
    • Kawasaki-shi, Kanagawa-Ken, Japan
      • Kanto Rosai Hospital
    • Yokohama-shi, Kanagawa-Ken, Japan
      • Yokohama City Eastern Hospital
  • Kumamoto-Ken
    • Kumamoto, Kumamoto-Ken, Japan
      • Kumamoto Rousai Hospital
  • Miyazaki-Ken
    • Miyazaki City, Miyazaki-Ken, Japan
      • Miyazaki Medical Association Hospital
  • Shiga-Ken
    • Hachiman, Shiga-Ken, Japan
      • Oumi Hachiman City General Medical Center
• New Zealand
  • Auckland, New Zealand
    • Auckland City Hospital
  • Auckland, New Zealand
    • Middlemore Clinical Trials Trust
  • Auckland, New Zealand
    • Waikato Hospital
  • Christchurch, New Zealand
    • Christchurch Hospital
  • Dunedin, New Zealand
    • Dunedin Hospital
  • Takapuna, New Zealand
    • North Shore Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

General Inclusion Criteria

Patients who meet all of the following criteria are eligible:

1. Patient must be ≥ 20 years of age.
2. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)
3. Patients who are able to take dual anti-platelet therapy for 1 year following the index procedure and anticoagulants prior to/during the index procedure.
4. The subject is an acceptable candidate for Percutaneous Transluminal Coronary Angioplasty (PTCA), stenting, and emergent Coronary Artery Bypass Graft (CABG) surgery.
5. The subject or subject's legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board or Ethics Committee of the respective clinical site.
6. Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing
7. Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing
8. Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure
9. Target lesion(s) must be de novo and located in a native coronary artery with a vessel mean diameter of ≥ 2.25 and ≤ 4.0 mm.
10. Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and < 100% with a TIMI flow of > 1. When two target lesions are treated, they must be located in separate major epicardial vessels
11. visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 14/15/18/23/28/32/38 mm ELX1805J stent and have at least 2 mm of healthy vessel on either side Or
12. The visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 15/18/22/30/34/38 mm ZES stent respectively and have at least 2 mm of healthy vessel on either side.
13. The lesion(s) must be successfully pre-dilated prior to enrollment Mandatory pre-dilatation includes the use of 2 orthogonal views to confirm lesion inclusion and exclusion criteria and successful pre-dilatation defined as balloon inflation without waist and a lumen diameter no less than 0.5 mm smaller than the vessel diameter.

14. Percutaneous intervention of lesions in a non-target vessel if:

    • Not part of a another clinical investigation
    • ≥ 30 days prior to the study index procedure
    • ≥ 6 months after the study index procedure (planned)

15. Percutaneous intervention of lesions located in the target vessel if:

    • Not part of a clinical investigation
    • ≥ 6 months prior to the study index procedure
    • >12 months after the study index procedure (planned)
    • Previous intervention was distal to and >10 mm from the target lesion

Exclusion Criteria:

1. The patient was diagnosed with an acute myocardial infarction within the past 72 hours and the CK and CKMB have not returned to normal (or cTn >15x ULN) and the patient is experiencing clinical symptoms indicative of ongoing ischemia
2. Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, cobalt, nickel, chromium, molybdenum, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated
3. Patients with a history of allergic reaction or serious hypersensitivity to drugs exhibiting interactions with sirolimus, zotarolimus, everolimus, tacrolimus, temsirolimus, biolimus and other rapamycin, derivatives or analogues) or similar drugs
4. Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors.
5. Patient presenting with chronic (permanent) atrial or ventricular arrhythmia or current unstable ventricular arrhythmias
6. Patient has a known left ventricular ejection fraction (LVEF) < 30%
7. Patient has received a heart or other organ transplant or is on a waiting list for any organ transplant
8. Patient has a malignancy that is not in remission.
9. Patient is receiving immunosuppression therapy other than steroids and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
10. Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures.
11. Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected to have cirrhosis of Child-Pugh ≥ Class B within 7 days before study procedure
12. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL within 7 days before study procedure, or patient on dialysis)
13. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
14. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months
15. Patient has had a significant GI or urinary bleed within the past six months
16. Patient has severe symptomatic heart failure (i.e., NYHA class IV)
17. Patient has a medical condition that precludes safe 6 French sheath insertion
18. Patient has other medical illness or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)
19. Patient is already participating in another clinical research study which has not reached the primary endpoint (long-term follow-up is not an exclusion)
20. Other patients whom primary investigator or subinvestigator determined to be ineligible for this clinical study
21. Patients with bypass graft to the target vessel or lesion is located in a bypass graft
22. Patients with stent implanted within 10 mm of proximal or distal end of target lesion

23. Patients with a target lesion involving a bifurcation of which the side branch will be jailed by the struts and:

    • Side branch ≥ 2.5 mm in diameter,
    • Side branch requiring predilatation (including Kissing Balloon Technique), or
    • Side branch has an ostial lesion or lesion with > 50% stenosis
24. Patients suspected or confirmed with the QCA analysis of having stenotic lesion of more than 50% in target vessel in addition to target lesion
25. Patients with target lesion in ostia located within 5 mm of origin of LAD, LCX or RCA
26. Patients with stenotic lesion in left main trunk
27. Patients with target lesion that is a chronic total occlusion (CTO) or ≤ TIMI 1 coronary flow in the target vessel
28. Patients with target vessel that contains thrombus as indicated in pre-procedure angiographic, IVUS or OCT images
29. Excessive tortuosity ≥ two 45° angles or extreme angulation (≥ 90°) proximal to or within the target lesion
30. Patients with target vessel that has moderate to severe calcification that prevents complete angioplasty balloon (POBA with non-compliant balloon, or scoring balloon,) inflation or requires other devices such as rotational atherectomy, rotoblator.
31. Patients with dissection of Grade A or B that cannot be covered (including 2mm distal to the dissection) with a single study device or with dissection of Grade C or higher
32. Patients with 2 or more target lesions on 1 branch or target lesions on 3 branches that need to be treated during study procedure
33. Target lesion involves a myocardial bridge

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Elixir Bioadaptor (ELX1805J); The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length	Device: Percutaneous Coronary Intervention; Percutaneous coronary intervention of de novo native coronary artery lesions
Active Comparator: Medtronic Resolute Onyx Stent; The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length	Device: Percutaneous Coronary Intervention; Percutaneous coronary intervention of de novo native coronary artery lesions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients with Target Lesion Failure (TLF)	TLF is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated	12 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients with Target Lesion Failure (TLF)	TLF is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated	30 Days, 180 Days, 2, 3, 4 and 5 years
Number of Patients with Patient Oriented Clinical Endpoint	Overall cardiovascular outcomes from the patient's perspective. This endpoint is a composite endpoint that includes all-cause mortality (cardiac and non-cardiac), stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Composite of All-cause mortality	A composite of all-cause mortality, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Composite of Cardiac Death TVMI and ID-TVR revascularization	Composite of cardiac death, target vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Cardiac death, stroke, MI and revascularization	Composite of cardiac death, stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Cardiac death, MI and revascularization	Composite of cardiac death, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Ischemia Driven Target Lesion Revascularization (ID-TLR)	Ischemia driven target lesion revascularization	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Target Lesion Revascularization (TLR)	Target lesion revascularization	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Target Vessel Revascularization (TVR)	Re-PCI or CABG of the target vessel due to in-segment restenosis or other complications	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Ischemia driven TVR (ID-TVR)	Re-PCI or CABG in the target vessel due to restenosis or other complications	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Revascularization (target vessel or non-target vessel)	Re-PCI or CABG of the target vessel due to in-segment restenosis or other complications	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Q-wave MI	CK post procedure is twice the upper limit of the reference value or higher, with new pathological Q-wave on 2 or more contiguous ECG leads and if CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Non Q-wave MI	CK post procedure is twice the upper limit of the reference value or higher, without new pathological Q-waves. If CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with MI (target vessel or non-target vessel)	per ARC II	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Target Vessel MI	per ARC II	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with All-cause Death	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Cardiac Death	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Composite of Cardiac Death or Target Vessel MI	Target Vessel Related Death or MI	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Composite of all-cause Death or MI	target vessel or non-target vessel related death or MI	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Composite of all-cause Death, MI (target vessel or non-target vessel), or TVR	Any Death, any MI and any Target Vessel Revascularization	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Composite of Probable or Definite Stent Thrombosis	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Probable Stent Thrombosis	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Number of Patients with Definite Stent Thrombosis	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years

Collaborators and Investigators

• Sponsor: Elixir Medical Corporation
• Investigators: Principal Investigator: Shigeru Saito, MD, Chief Director, Shonan Kamakura General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 16, 2020
• Primary Completion (Actual): February 28, 2023
• Study Completion (Estimated): February 28, 2027

Study Registration Dates

• First Submitted: December 6, 2019
• First Submitted That Met QC Criteria: December 6, 2019
• First Posted (Actual): December 10, 2019

Study Record Updates

• Last Update Posted (Actual): September 7, 2023
• Last Update Submitted That Met QC Criteria: September 5, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Percutaneous Coronary Intervention; Coronary Ste; Bioadaptor
• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Pathological Conditions, Anatomical; Coronary Artery Disease; Coronary Disease; Constriction, Pathologic; Coronary Stenosis
• Other Study ID Numbers: ELX-CL-1805

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes